High-throughput oncogene mutation profiling in human cancer
- PMID: 17293865
- DOI: 10.1038/ng1975
High-throughput oncogene mutation profiling in human cancer
Erratum in
- Nat Genet. 2007 Apr;39(4):567. Macconnaill, Laura E [corrected to MacConaill, Laura]
Abstract
Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression. However, widespread clinical application of this information is hampered by an inability to identify critical genetic events across the spectrum of human tumors with adequate sensitivity and scalability. Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples. This approach established robust mutation distributions spanning 17 cancer types. Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation. Moreover, we identified previously unrecognized oncogene mutations in several tumor types and observed an unexpectedly high number of co-occurring mutations. These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention.
Comment in
-
The devil is in the DNA.Nat Genet. 2007 Mar;39(3):283-4. doi: 10.1038/ng0307-283. Nat Genet. 2007. PMID: 17325673 No abstract available.
Similar articles
-
Identification and analysis of mutational hotspots in oncogenes and tumour suppressors.Oncotarget. 2017 Mar 28;8(13):21290-21304. doi: 10.18632/oncotarget.15514. Oncotarget. 2017. PMID: 28423505 Free PMC article.
-
High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.Clin Cancer Res. 2014 Apr 15;20(8):2080-91. doi: 10.1158/1078-0432.CCR-13-3114. Epub 2014 Feb 26. Clin Cancer Res. 2014. PMID: 24573554
-
Profiling critical cancer gene mutations in clinical tumor samples.PLoS One. 2009 Nov 18;4(11):e7887. doi: 10.1371/journal.pone.0007887. PLoS One. 2009. PMID: 19924296 Free PMC article.
-
High-throughput mutational analysis of the human cancer genome.Pharmacogenomics. 2006 Jun;7(4):597-612. doi: 10.2217/14622416.7.4.597. Pharmacogenomics. 2006. PMID: 16753007 Review.
-
Mutational analysis of gene families in human cancer.Curr Opin Genet Dev. 2005 Feb;15(1):5-12. doi: 10.1016/j.gde.2004.12.009. Curr Opin Genet Dev. 2005. PMID: 15661527 Review.
Cited by
-
MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon.Front Oncol. 2024 Apr 30;14:1387535. doi: 10.3389/fonc.2024.1387535. eCollection 2024. Front Oncol. 2024. PMID: 38746674 Free PMC article.
-
Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province.Sci Rep. 2024 Mar 29;14(1):7495. doi: 10.1038/s41598-024-58092-w. Sci Rep. 2024. PMID: 38553524 Free PMC article.
-
A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.Commun Biol. 2024 Jan 5;7(1):26. doi: 10.1038/s42003-023-05639-8. Commun Biol. 2024. PMID: 38182748 Free PMC article.
-
The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.Nat Commun. 2023 Sep 4;14(1):5391. doi: 10.1038/s41467-023-41011-4. Nat Commun. 2023. PMID: 37666855 Free PMC article.
-
A Case-Control Study of the Relationship Between Genetic Polymorphism and Cretinism in Xinjiang.Pharmgenomics Pers Med. 2023 Aug 23;16:785-794. doi: 10.2147/PGPM.S418722. eCollection 2023. Pharmgenomics Pers Med. 2023. PMID: 37641720 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources